Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ROIV |
---|---|---|
09:32 ET | 197109 | 11.35 |
09:34 ET | 29534 | 11.324 |
09:36 ET | 75146 | 11.3475 |
09:38 ET | 36437 | 11.29 |
09:39 ET | 57345 | 11.24 |
09:41 ET | 47573 | 11.245 |
09:43 ET | 26277 | 11.235 |
09:45 ET | 52795 | 11.23 |
09:48 ET | 9433 | 11.29 |
09:50 ET | 15373 | 11.325 |
09:52 ET | 22190 | 11.315 |
09:54 ET | 29690 | 11.305 |
09:56 ET | 20090 | 11.285 |
09:57 ET | 16236 | 11.2802 |
09:59 ET | 4632 | 11.305 |
10:01 ET | 13148 | 11.32 |
10:03 ET | 43482 | 11.325 |
10:06 ET | 33684 | 11.345 |
10:08 ET | 13505 | 11.335 |
10:10 ET | 11841 | 11.36 |
10:12 ET | 28971 | 11.37 |
10:14 ET | 7625 | 11.37 |
10:15 ET | 7475 | 11.375 |
10:17 ET | 6527 | 11.375 |
10:19 ET | 6858 | 11.395 |
10:21 ET | 9606 | 11.4 |
10:24 ET | 11301 | 11.36 |
10:26 ET | 18773 | 11.36 |
10:28 ET | 14681 | 11.365 |
10:30 ET | 10992 | 11.355 |
10:32 ET | 20137 | 11.325 |
10:33 ET | 16042 | 11.34 |
10:35 ET | 26312 | 11.34 |
10:37 ET | 8972 | 11.325 |
10:39 ET | 8688 | 11.32 |
10:42 ET | 10095 | 11.32 |
10:44 ET | 35804 | 11.33 |
10:46 ET | 11210 | 11.325 |
10:48 ET | 8424 | 11.32 |
10:50 ET | 4092 | 11.32 |
10:51 ET | 25962 | 11.325 |
10:53 ET | 97758 | 11.335 |
10:55 ET | 5298 | 11.325 |
10:57 ET | 3512 | 11.32 |
11:00 ET | 6573 | 11.31 |
11:02 ET | 13073 | 11.315 |
11:04 ET | 13067 | 11.31 |
11:06 ET | 34785 | 11.305 |
11:08 ET | 6705 | 11.305 |
11:09 ET | 20455 | 11.29 |
11:11 ET | 41719 | 11.28 |
11:13 ET | 5194 | 11.275 |
11:15 ET | 7176 | 11.275 |
11:18 ET | 18176 | 11.275 |
11:20 ET | 9904 | 11.28 |
11:22 ET | 13465 | 11.275 |
11:24 ET | 27178 | 11.25 |
11:26 ET | 12873 | 11.2404 |
11:27 ET | 11074 | 11.245 |
11:29 ET | 34257 | 11.285 |
11:31 ET | 3721 | 11.29 |
11:33 ET | 13576 | 11.27 |
11:36 ET | 15822 | 11.285 |
11:38 ET | 10181 | 11.285 |
11:40 ET | 10423 | 11.27 |
11:42 ET | 5259 | 11.27 |
11:44 ET | 15382 | 11.28 |
11:45 ET | 5360 | 11.285 |
11:47 ET | 16840 | 11.285 |
11:49 ET | 4869 | 11.2999 |
11:51 ET | 5649 | 11.3 |
11:54 ET | 24672 | 11.285 |
11:56 ET | 2703 | 11.285 |
11:58 ET | 15119 | 11.275 |
12:00 ET | 1400 | 11.275 |
12:02 ET | 72555 | 11.275 |
12:03 ET | 47140 | 11.265 |
12:05 ET | 80685 | 11.265 |
12:07 ET | 2381 | 11.265 |
12:09 ET | 40024 | 11.25 |
12:12 ET | 2747 | 11.25 |
12:14 ET | 4080 | 11.255 |
12:16 ET | 14835 | 11.27 |
12:18 ET | 26816 | 11.255 |
12:20 ET | 11472 | 11.255 |
12:21 ET | 32174 | 11.245 |
12:23 ET | 15794 | 11.245 |
12:25 ET | 13126 | 11.255 |
12:27 ET | 3535 | 11.255 |
12:30 ET | 40899 | 11.26 |
12:32 ET | 29851 | 11.25 |
12:34 ET | 24988 | 11.255 |
12:36 ET | 4731 | 11.25 |
12:38 ET | 37568 | 11.255 |
12:39 ET | 11116 | 11.26 |
12:41 ET | 5153 | 11.265 |
12:43 ET | 32133 | 11.255 |
12:45 ET | 5506 | 11.25 |
12:48 ET | 22457 | 11.245 |
12:50 ET | 11160 | 11.25 |
12:52 ET | 14337 | 11.25 |
12:54 ET | 7320 | 11.255 |
12:56 ET | 3937 | 11.255 |
12:57 ET | 47668 | 11.235 |
12:59 ET | 3346 | 11.235 |
01:01 ET | 21464 | 11.235 |
01:03 ET | 33843 | 11.225 |
01:06 ET | 21330 | 11.23 |
01:08 ET | 3654 | 11.235 |
01:10 ET | 20792 | 11.24 |
01:12 ET | 12600 | 11.235 |
01:14 ET | 7205 | 11.235 |
01:15 ET | 1300 | 11.23 |
01:17 ET | 4318 | 11.235 |
01:19 ET | 8995 | 11.235 |
01:21 ET | 14830 | 11.245 |
01:24 ET | 7694 | 11.255 |
01:26 ET | 19396 | 11.24 |
01:28 ET | 7291 | 11.245 |
01:30 ET | 20089 | 11.25 |
01:32 ET | 22209 | 11.24 |
01:33 ET | 34901 | 11.25 |
01:35 ET | 266828 | 11.225 |
01:37 ET | 21092 | 11.25 |
01:39 ET | 12658 | 11.25 |
01:42 ET | 8854 | 11.25 |
01:44 ET | 31056 | 11.255 |
01:46 ET | 15995 | 11.255 |
01:48 ET | 42710 | 11.275 |
01:50 ET | 46718 | 11.285 |
01:51 ET | 11294 | 11.295 |
01:53 ET | 40711 | 11.29 |
01:55 ET | 7220 | 11.285 |
01:57 ET | 7302 | 11.285 |
02:00 ET | 6086 | 11.285 |
02:02 ET | 15889 | 11.295 |
02:04 ET | 11183 | 11.305 |
02:06 ET | 33395 | 11.305 |
02:08 ET | 2952 | 11.305 |
02:09 ET | 6701 | 11.305 |
02:11 ET | 6678 | 11.305 |
02:13 ET | 10493 | 11.3177 |
02:15 ET | 4654 | 11.315 |
02:18 ET | 4894 | 11.315 |
02:20 ET | 5363 | 11.315 |
02:22 ET | 32383 | 11.315 |
02:24 ET | 6529 | 11.31 |
02:26 ET | 8195 | 11.31 |
02:27 ET | 58970 | 11.315 |
02:29 ET | 35694 | 11.32 |
02:31 ET | 21487 | 11.325 |
02:33 ET | 21662 | 11.335 |
02:36 ET | 3865 | 11.335 |
02:38 ET | 2591 | 11.335 |
02:40 ET | 24641 | 11.3388 |
02:42 ET | 2189 | 11.33 |
02:44 ET | 7793 | 11.33 |
02:45 ET | 52610 | 11.335 |
02:47 ET | 1956 | 11.33 |
02:49 ET | 3368 | 11.335 |
02:51 ET | 20321 | 11.33 |
02:54 ET | 20432 | 11.32 |
02:56 ET | 7361 | 11.325 |
02:58 ET | 8658 | 11.325 |
03:00 ET | 24408 | 11.3207 |
03:02 ET | 4298 | 11.325 |
03:03 ET | 13249 | 11.32 |
03:05 ET | 7227 | 11.32 |
03:07 ET | 7581 | 11.32 |
03:09 ET | 85719 | 11.31 |
03:12 ET | 43847 | 11.31 |
03:14 ET | 3754 | 11.315 |
03:16 ET | 6962 | 11.31 |
03:18 ET | 80425 | 11.29 |
03:20 ET | 28675 | 11.28 |
03:21 ET | 19027 | 11.29 |
03:23 ET | 13874 | 11.28 |
03:25 ET | 21826 | 11.275 |
03:27 ET | 1319 | 11.275 |
03:30 ET | 1608 | 11.27 |
03:32 ET | 4244 | 11.275 |
03:34 ET | 14959 | 11.27 |
03:36 ET | 106897 | 11.285 |
03:38 ET | 19010 | 11.295 |
03:39 ET | 38400 | 11.285 |
03:41 ET | 4220 | 11.285 |
03:43 ET | 35171 | 11.275 |
03:45 ET | 40018 | 11.27 |
03:48 ET | 10293 | 11.275 |
03:50 ET | 12130 | 11.27 |
03:52 ET | 121426 | 11.245 |
03:54 ET | 37161 | 11.24 |
03:56 ET | 85556 | 11.255 |
03:57 ET | 95676 | 11.279 |
03:59 ET | 621574 | 11.28 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Roivant Sciences Ltd | 8.4B | 2.0x | --- |
Corcept Therapeutics Inc | 4.9B | 40.3x | +9.80% |
Ligand Pharmaceuticals Inc | 1.9B | 44.9x | -12.71% |
Harrow Inc | 1.6B | -48.3x | --- |
Ocular Therapeutix Inc | 1.4B | -8.5x | --- |
Immunocore Holdings PLC | 1.6B | -29.0x | --- |
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 for the treatment of dermatomyositis and non-infectious uveitis, in addition to other clinical-stage molecules. It advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its pipeline program also includes Mosliciguat.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.4B |
---|---|
Revenue (TTM) | $158.3M |
Shares Outstanding | 739.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $5.57 |
Book Value | $7.40 |
P/E Ratio | 2.0x |
Price/Sales (TTM) | 53.1 |
Price/Cash Flow (TTM) | 1.8x |
Operating Margin | 2,799.07% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.